STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	Appendix 4G - Corporate Governance Statement		21/08/15	315.7KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/07/15	131.89KB	Share
SPL	Change in substantial holding		30/06/15	35.65KB	Share
SPL	Becoming a substantial holder		10/06/15	40.63KB	Share
SPL	Change in Director's Interest Notice - J Fairley		27/05/15	72.43KB	Share
SPL	Change in substantial holding		08/05/15	151.28KB	Share
SPL	AstraZeneca to develop oncology drug using DEP technology		04/05/15	135.69KB	Share
SPL	Ceasing to be a substantial holder		01/05/15	52.42KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/04/15	158.2KB	Share
SPL	DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level	PRICE SENSITIVE	30/04/15	361.15KB	Share
SPL	Securities Dealing Policy		22/04/15	71.84KB	Share
SPL	Shareholder Update March 2015		23/03/15	1.89MB	Share
SPL	Shareholder Update March 2015		23/03/15	1.89MB	Share
SPL	Starpharma to present at March US investor conferences		05/03/15	93.23KB	Share
SPL	Starpharma presents at ASX Investor Series		17/02/15	106.27KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	16/02/15	416.1KB	Share
SPL	Appendix 3B		30/01/15	150.62KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	28/01/15	322.29KB	Share
SPL	Appendix 3B		22/01/15	153.36KB	Share
SPL	Starpharma to present at Biotech Showcase		12/01/15	105.99KB	Share
SPL	Appendix 3B		23/12/14	153.67KB	Share
SPL	Change in Director's Interest Notice - R Thomas		18/12/14	71.65KB	Share
SPL	Change in substantial holding		17/12/14	55.13KB	Share
SPL	Change in Director's Interest Notice - J Fairley		17/12/14	71.97KB	Share
SPL	Change in Director's Interest Notice - R Thomas		08/12/14	71.79KB	Share
SPL	Japan VivaGel condom classification impacts launch timing	PRICE SENSITIVE	05/12/14	388.32KB	Share
SPL	Change in Director's Interest Notice - J Fairley		03/12/14	228.97KB	Share
SPL	Appendix 3B		03/12/14	165.75KB	Share
SPL +ANN EBO	Marketing Clearance for VivaGel condom in New Zealand	PRICE SENSITIVE	28/11/14	110.33KB	Share
SPL	Change of Company Address		27/11/14	96.31KB	Share
SPL	Starpharma Adopts New Constitution		20/11/14	13.21MB	Share
SPL	AGM Results		20/11/14	111.17KB	Share
SPL	AGM - Chair Address and CEO's Presentation		20/11/14	2.4MB	Share
SPL	Response to ASX Price Query	PRICE SENSITIVE	17/11/14	104.56KB	Share
SPL	Starpharmas Priostar Glyphosate Patent Allowed in China	PRICE SENSITIVE	13/11/14	97.26KB	Share
SPL	Change in Director's Interest Notice - R Hazleton		06/11/14	71.74KB	Share
SPL	Change in Director's Interest Notice - P Turvey		06/11/14	72.67KB	Share
SPL	Change in Director's Interest Notice - Z Peach		06/11/14	72.7KB	Share
SPL	Change in Director's Interest Notice - P Jenkins		06/11/14	77.52KB	Share
SPL	Change in Director's Interest Notice - R Thomas		06/11/14	73.15KB	Share
SPL	Change of Director's Interest Notice - J Fairley		06/11/14	73.24KB	Share
SPL	Appendix 3B - SPP		05/11/14	158.04KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	119.31KB	Share
SPL	Starpharma raises $3.5M through SPP following $18M Placement		30/10/14	103.08KB	Share
SPL	Starpharma receives $4.2M R&D tax incentive refund	PRICE SENSITIVE	29/10/14	96.34KB	Share
SPL +ANN	VivaGel condom now available in Australian stores		29/10/14	394.83KB	Share
SPL	Share Purchase Plan		28/10/14	104.23KB	Share
SPL	Starpharma Boardroom Radio Interview		21/10/14	77.78KB	Share
SPL	Extension of Share Purchase Plan		20/10/14	81.87KB	Share
SPL	DEP docetaxel - longer duration and increased exposure	PRICE SENSITIVE	20/10/14	114.28KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		16/10/14	554.82KB	Share
SPL	Change of Director's Interest Notice		14/10/14	72.65KB	Share
SPL	Appendix 3B		14/10/14	142.57KB	Share
SPL	Starpharma to present at US Drug Delivery Conference		14/10/14	95.35KB	Share
SPL	Shareholder Update October 2014		07/10/14	1.57MB	Share
SPL	Change in substantial holding		03/10/14	58.38KB	Share
SPL +ANN	VivaGel condom approved for sale with launch imminent	PRICE SENSITIVE	02/10/14	114.51KB	Share
SPL	Date of Annual General Meeting		01/10/14	307.78KB	Share
SPL	Change in substantial holding - correction		01/10/14	224.78KB	Share
SPL	Change in substantial holding		30/09/14	222.33KB	Share
SPL	Cleansing Statement		29/09/14	101.69KB	Share
SPL	Appendix 3B - Share Placement		29/09/14	153.16KB	Share
SPL	Share Purchase Plan offer documents		26/09/14	678.45KB	Share
SPL	Appendix 3B		25/09/14	259.36KB	Share
SPL	SPP Record Date Clarification	PRICE SENSITIVE	22/09/14	90.53KB	Share
SPL	Starpharma completes A$18 million placement, SPP to follow	PRICE SENSITIVE	22/09/14	98.94KB	Share
SPL	Trading Halt	PRICE SENSITIVE	18/09/14	265.77KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	13/08/14	4.21MB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	31/07/14	147.28KB	Share
SPL	VivaGel condom receives TGA device certification	PRICE SENSITIVE	21/07/14	108.69KB	Share
SPL	FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial	PRICE SENSITIVE	14/07/14	95.26KB	Share
SPL	Change of Director's Interest Notice		01/07/14	72.35KB	Share
SPL	Change of Director's Interest Notice		24/06/14	71.4KB	Share
SPL	Appendix 3B		18/06/14	144.73KB	Share
SPL	Final Director's Interest Notice		18/06/14	60.79KB	Share
SPL	Correction to Shareholder Update June 2014		13/06/14	2.09MB	Share
SPL	Rob Thomas succeeds retiring Chairman Peter Bartels		13/06/14	92.39KB	Share
SPL	Shareholder Update June 2014		12/06/14	1.62MB	Share
SPL	Ceasing to be a substantial holder		10/06/14	82.32KB	Share
SPL	Becoming a substantial holder		06/06/14	369.04KB	Share
SPL	Starpharma clinical trial programs accelerating	PRICE SENSITIVE	05/06/14	114.57KB	Share
SPL	Change in substantial holding		30/05/14	92KB	Share
SPL	Appendix 3B		22/05/14	144.47KB	Share
SPL	Change in substantial holding		16/05/14	58.42KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/04/14	110.39KB	Share
SPL	Starpharma expands Drug Delivery Program with AstraZeneca	PRICE SENSITIVE	07/04/14	104.72KB	Share
SPL	VivaGel-coated condom approved for marketing in Japan	PRICE SENSITIVE	14/03/14	189.96KB	Share
SPL	Starpharma receives $4.7M R&D tax incentive		11/03/14	335.41KB	Share
SPL	Starpharma to present to US institutional investors		27/02/14	2.69MB	Share
SPL	Starpharma Interim Report and Half-year Financial Results	PRICE SENSITIVE	24/02/14	706.53KB	Share
SPL	Appendix 3B		19/02/14	144KB	Share
SPL	Appendix 3B		30/01/14	307.69KB	Share
SPL	Appendix 4C - Quarterly Cashflow Report	PRICE SENSITIVE	30/01/14	316.05KB	Share
SPL	Change in substantial holding		28/01/14	91.77KB	Share
SPL	Response to ASX Price Query	PRICE SENSITIVE	23/01/14	1.79MB	Share
SPL	Starpharma commences Dendrimer-Docetaxel clinical trial	PRICE SENSITIVE	23/01/14	364.44KB	Share
SPL	Change in substantial holding		14/01/14	58.34KB	Share
SPL	Starpharma to recoup additional $2 million for overseas R&D	PRICE SENSITIVE	14/01/14	95.02KB	Share
SPL	Cancer Australia funding for dendrimer-based lung treatment	PRICE SENSITIVE	19/12/13	453.46KB	Share
SPL	Shareholder Update December 2013		17/12/13	1.46MB	Share

SPL Appendix 4G - Corporate Governance Statement
21/08/15		315.7KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/07/15	PRICE SENSITIVE	131.89KB	Share
SPL Change in substantial holding
30/06/15		35.65KB	Share
SPL Becoming a substantial holder
10/06/15		40.63KB	Share
SPL Change in Director's Interest Notice - J Fairley
27/05/15		72.43KB	Share
SPL Change in substantial holding
08/05/15		151.28KB	Share
SPL AstraZeneca to develop oncology drug using DEP technology
04/05/15		135.69KB	Share
SPL Ceasing to be a substantial holder
01/05/15		52.42KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
30/04/15	PRICE SENSITIVE	158.2KB	Share
SPL DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level
30/04/15	PRICE SENSITIVE	361.15KB	Share
SPL Securities Dealing Policy
22/04/15		71.84KB	Share
SPL Shareholder Update March 2015
23/03/15		1.89MB	Share
SPLShareholder Update March 2015
23/03/15		1.89MB	Share
SPL Starpharma to present at March US investor conferences
05/03/15		93.23KB	Share
SPL Starpharma presents at ASX Investor Series
17/02/15		106.27KB	Share
SPL Interim Report and Half-Year Financial Results
16/02/15	PRICE SENSITIVE	416.1KB	Share
SPL Appendix 3B
30/01/15		150.62KB	Share
SPL Appendix 4C - Quarterly Cashflow Report
28/01/15	PRICE SENSITIVE	322.29KB	Share
SPL Appendix 3B
22/01/15		153.36KB	Share
SPL Starpharma to present at Biotech Showcase
12/01/15		105.99KB	Share
SPL Appendix 3B
23/12/14		153.67KB	Share
SPL Change in Director's Interest Notice - R Thomas
18/12/14		71.65KB	Share
SPL Change in substantial holding
17/12/14		55.13KB	Share
SPL Change in Director's Interest Notice - J Fairley
17/12/14		71.97KB	Share
SPL Change in Director's Interest Notice - R Thomas
08/12/14		71.79KB	Share
SPL Japan VivaGel condom classification impacts launch timing
05/12/14	PRICE SENSITIVE	388.32KB	Share
SPL Change in Director's Interest Notice - J Fairley
03/12/14		228.97KB	Share
SPL Appendix 3B
03/12/14		165.75KB	Share
SPL +ANN EBO Marketing Clearance for VivaGel condom in New Zealand
28/11/14	PRICE SENSITIVE	110.33KB	Share
SPL Change of Company Address
27/11/14		96.31KB	Share
SPL Starpharma Adopts New Constitution
20/11/14		13.21MB	Share
SPL AGM Results
20/11/14		111.17KB	Share
SPL AGM - Chair Address and CEO's Presentation
20/11/14		2.4MB	Share
SPL Response to ASX Price Query
17/11/14	PRICE SENSITIVE	104.56KB	Share
SPL Starpharmas Priostar Glyphosate Patent Allowed in China
13/11/14	PRICE SENSITIVE	97.26KB	Share
SPL Change in Director's Interest Notice - R Hazleton
06/11/14		71.74KB	Share
SPL Change in Director's Interest Notice - P Turvey
06/11/14		72.67KB	Share
SPL Change in Director's Interest Notice - Z Peach
06/11/14		72.7KB	Share
SPL Change in Director's Interest Notice - P Jenkins
06/11/14		77.52KB	Share
SPL Change in Director's Interest Notice - R Thomas
06/11/14		73.15KB	Share
SPL Change of Director's Interest Notice - J Fairley
06/11/14		73.24KB	Share
SPL Appendix 3B - SPP
05/11/14		158.04KB	Share
SPL Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	119.31KB	Share
SPL Starpharma raises $3.5M through SPP following $18M Placement
30/10/14		103.08KB	Share
SPL Starpharma receives $4.2M R&D tax incentive refund
29/10/14	PRICE SENSITIVE	96.34KB	Share
SPL +ANN VivaGel condom now available in Australian stores
29/10/14		394.83KB	Share
SPL Share Purchase Plan
28/10/14		104.23KB	Share
SPL Starpharma Boardroom Radio Interview
21/10/14		77.78KB	Share
SPL Extension of Share Purchase Plan
20/10/14		81.87KB	Share
SPL DEP docetaxel - longer duration and increased exposure
20/10/14	PRICE SENSITIVE	114.28KB	Share
SPL Notice of Annual General Meeting/Proxy Form
16/10/14		554.82KB	Share
SPL Change of Director's Interest Notice
14/10/14		72.65KB	Share
SPL Appendix 3B
14/10/14		142.57KB	Share
SPL Starpharma to present at US Drug Delivery Conference
14/10/14		95.35KB	Share
SPL Shareholder Update October 2014
07/10/14		1.57MB	Share
SPL Change in substantial holding
03/10/14		58.38KB	Share
SPL +ANN VivaGel condom approved for sale with launch imminent
02/10/14	PRICE SENSITIVE	114.51KB	Share
SPL Date of Annual General Meeting
01/10/14		307.78KB	Share
SPL Change in substantial holding - correction
01/10/14		224.78KB	Share
SPL Change in substantial holding
30/09/14		222.33KB	Share
SPL Cleansing Statement
29/09/14		101.69KB	Share
SPL Appendix 3B - Share Placement
29/09/14		153.16KB	Share
SPL Share Purchase Plan offer documents
26/09/14		678.45KB	Share
SPL Appendix 3B
25/09/14		259.36KB	Share
SPL SPP Record Date Clarification
22/09/14	PRICE SENSITIVE	90.53KB	Share
SPL Starpharma completes A$18 million placement, SPP to follow
22/09/14	PRICE SENSITIVE	98.94KB	Share
SPL Trading Halt
18/09/14	PRICE SENSITIVE	265.77KB	Share
SPL Annual report and full year financial results
13/08/14	PRICE SENSITIVE	4.21MB	Share
SPL Appendix 4C - Quarterly Cashflow Report
31/07/14	PRICE SENSITIVE	147.28KB	Share
SPL VivaGel condom receives TGA device certification
21/07/14	PRICE SENSITIVE	108.69KB	Share
SPL FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
14/07/14	PRICE SENSITIVE	95.26KB	Share
SPL Change of Director's Interest Notice
01/07/14		72.35KB	Share
SPL Change of Director's Interest Notice
24/06/14		71.4KB	Share
SPL Appendix 3B
18/06/14		144.73KB	Share
SPL Final Director's Interest Notice
18/06/14		60.79KB	Share
SPL Correction to Shareholder Update June 2014
13/06/14		2.09MB	Share
SPL Rob Thomas succeeds retiring Chairman Peter Bartels
13/06/14		92.39KB	Share
SPL Shareholder Update June 2014
12/06/14		1.62MB	Share
SPL Ceasing to be a substantial holder
10/06/14		82.32KB	Share
SPLBecoming a substantial holder
06/06/14		369.04KB	Share
SPLStarpharma clinical trial programs accelerating
05/06/14	PRICE SENSITIVE	114.57KB	Share
SPLChange in substantial holding
30/05/14		92KB	Share
SPLAppendix 3B
22/05/14		144.47KB	Share
SPLChange in substantial holding
16/05/14		58.42KB	Share
SPLAppendix 4C - Quarterly Cashflow Report
30/04/14	PRICE SENSITIVE	110.39KB	Share
SPLStarpharma expands Drug Delivery Program with AstraZeneca
07/04/14	PRICE SENSITIVE	104.72KB	Share
SPLVivaGel-coated condom approved for marketing in Japan
14/03/14	PRICE SENSITIVE	189.96KB	Share
SPLStarpharma receives $4.7M R&D tax incentive
11/03/14		335.41KB	Share
SPLStarpharma to present to US institutional investors
27/02/14		2.69MB	Share
SPLStarpharma Interim Report and Half-year Financial Results
24/02/14	PRICE SENSITIVE	706.53KB	Share
SPLAppendix 3B
19/02/14		144KB	Share
SPLAppendix 3B
30/01/14		307.69KB	Share
SPLAppendix 4C - Quarterly Cashflow Report
30/01/14	PRICE SENSITIVE	316.05KB	Share
SPLChange in substantial holding
28/01/14		91.77KB	Share
SPLResponse to ASX Price Query
23/01/14	PRICE SENSITIVE	1.79MB	Share
SPLStarpharma commences Dendrimer-Docetaxel clinical trial
23/01/14	PRICE SENSITIVE	364.44KB	Share
SPLChange in substantial holding
14/01/14		58.34KB	Share
SPLStarpharma to recoup additional $2 million for overseas R&D
14/01/14	PRICE SENSITIVE	95.02KB	Share
SPLCancer Australia funding for dendrimer-based lung treatment
19/12/13	PRICE SENSITIVE	453.46KB	Share
SPLShareholder Update December 2013
17/12/13		1.46MB	Share

REFRESH

First 5 6 7 8 9

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories